Efficacy and Safety of Standard Triple Therapy for Helicobacter pylori Eradication in Latin America A Systematic Review and Meta-Analysis

Goals: To evaluate the efficacy and safety of standard triple therapy (STT) in Latin America. Background: Helicobacter pylori infection affects more than 50% of the Latin Americans and leads to gastric mucosa damage. Scarce data on effective therapeutic approaches in the region underscores the need for comprehensive information. Study: The analysis included Randomized Controlled Trials published up to the year 2020, comparing STT with other treatments. Cumulative relative risks (RR) were estimated, with 95% CI, according to intention-to-treat (ITT) and per protocol (PP) analysis. Results: Eleven studies (clinical trials conducted between 1995 and 2013), revealed cumulative eradication rates of 78.31–90.63% (ITT) and 76.71–93.55% (PP). The eradication with the STT was superior to sequential therapy (ITT—RR: 10.6, 95% CI: 1.01 to 1.12) (PP—RR: 10.6, 95% CI: 1.02-1.11) and dual therapy (ITT—RR: 1.61, 95% CI: 1.13-2.30) (PP—RR: 1.72, 95% CI: 1.25-2.37), but is less effective than other triple therapies (PP—RR: 0.85, 95% CI: 0.78-092). Regarding adverse effects, diarrhea, metallic taste, nausea, vomiting, and headache were the most common symptoms across treatments. Abdominal pain was associated with STT (ITT—RR: 1.75, 95% CI: 1.07-2.86). Conclusion: STT was a safe regimen but with acceptable efficacy (most eradication rates < 90%). Due to rising clarithromycin resistance, the study suggests avoiding STT as a first-line treatment. These results must be considered with caution due to the low representativeness of several Latin American countries and the lack of recent high-quality randomized studies.